ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This study evaluates the anti-tumor effects of ORIN 1001 in patients with advanced solid tumors or relapsed refractory metastatic breast cancer (patients with progressive disease after receiving at least two lines of therapy in the advanced setting).
Epistemonikos ID: acda3daf2b0c71556c59197ccea543b6a93e395a
First added on: May 22, 2024